AstraZeneca's Ondexxya wins approval for reversal of acute major bleeds in patients
Ondexxya was also approved in Japan for use along with all three FXa inhibitors: apixaban, rivaroxaban, or edoxaban
Company
AstraZeneca PLC
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1084 stories · page 17 of 55
AstraZeneca's COVID drug bags EU approval
Evusheld may be particularly beneficial for people not adequately protected by a COVID-19 vaccine
AstraZeneca's Imfinzi fails to meet primary endpoint in phase 3 cervical cancer trial
“While the results were not what we hoped for, insights from the trial will advance our understanding and application of immunotherapy across our broad clinical development programme, exploring the benefits of Imfinzi in many tumour types,”
AstraZeneca ready to drop US approval attempt for Covid vaccine - report
Shares in AstraZeneca are at their highest level ever
AstraZeneca’s COVID vaccine alternative gets UK green light
While vaccines are seen as the first-line defence against COVID-19, the medical regulator said this drug was for those who "may not respond adequately to these vaccines and for a small number of individuals COVID-19 vaccines may not be reco
AstraZeneca to pay US$775mln to settle Alexion patent dispute
The litigation with the Chugai Pharmaceutical Company relates to a drug called Ultomiris
AstraZeneca's COVID-19 drug application under review by EU regulators
The EU drug regulator began reviewing the data on AstraZeneca's antibody cocktail last October
Nine FTSE companies to hedge the risk of Russia's invasion of Ukraine
“Hedging macro risk is likely to remain important for equity investors in the near term,” the analysts said
AstraZeneca and Neurimmune land US$760mln deal for heart disease drug
Deal will see AstraZeneca's subsidiary develop, manufacture and commercialise NI006, with initial payment to Neurimmune of US$30mln
AstraZeneca’s Enhertu shown to improve survival in breast cancer patients in pivotal trial
The trial results offer the potential to redefine how the disease is classified and treated, the drug giant said
AstraZeneca EU wins approval for the first drug in more than a decade for lupus
AZ's Saphnelo works by dampening the excessive type I interferon signature that is found in many patients
AstraZeneca drug could help prolong life of terminally ill prostate cancer patients
AZ's Lynparza in combination with a common hormone therapy delayed disease progression versus the current standard of care by more than eight months
AstraZeneca boosted by Alexion acquisition; five newly-minted blockbusters join its medicine cabinet
Revenues grew 41% with core EPS up 32%; the Anglo-Swedish giant remains bullish on the outlook
AstraZeneca looks beyond Covid, US inflation and Unilever under pressure: Thursday's agenda
Another set of big names reports tomorrow while price rises in the US will set the afternoon tone
Will Pfizer's success push AstraZeneca and GlaxoSmithKline investors over the edge?
Pfizer expects to receive a continued boost from its Covid jab. Investors in AZ and GSK will likely look on in envy
AstraZeneca Covid jab criticism cost 'hundreds of thousands' of lives claims professor
“Bad behaviour from scientists and from politicians has probably killed hundreds of thousands of people"
AstraZeneca PLC cancer drug offers hope to sufferers of a rare but aggressive form of the disease
The company's treatment Imfinzi when used with chemotherapy reduced the risk of death by 20% in patients with advanced biliary tract cancer
AstraZeneca PLC cancer drug offers hope to sufferers of a rare but aggressive form of the disease
The company's treatment Imfinzi when used with chemotherapy reduced the risk of death by 20% in patients with advanced biliary tract cancer
Investments and investor services
AstraZeneca's Enhertu granted Priority Review for breast cancer in US
In a trial, Enhertu reduced the risk of disease progression or death by 72% versus a prior treatment
AstraZeneca and Neurimmune sign deal to develop and commercialise treatment for fatal condition ATTR-CM
Neurimmune will receive an upfront payment of US$30mln from Alexion with potential milestone payments of up to US$730mln